SCHAUMBURG, Ill., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Paclitaxel Injection, USP, a chemotherapy drug, in 30 mg, 100 mg and 300 mg latex-free, multi-dose vials. According to IMS, the 2011 U.S. market for generic injectable paclitaxel approximates $46 million. As with all products in Sagent's portfolio, paclitaxel features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
"Paclitaxel is currently on the American Society of Health-System Pharmacists' and the U.S. FDA drug shortage lists and we are pleased to be able to help supply this vital chemotherapy option to patients," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The launch of paclitaxel expands our rapidly growing portfolio of injectable oncolytics to six products."
About Paclitaxel Injection
Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma. More specifically:
- First-line and subsequent therapy for the treatment of advanced ovarian cancer. As first-line therapy, paclitaxel is indicated in combination with cisplatin (chemotherapy).
- Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
- Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
- In combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
- Second-line treatment of AIDS-related Kaposi's sarcoma (cancer of connective tissue).
Detailed information about the indications, warnings, complete side effect profile, and full prescribing information will be available in the package insert. Please visit www.SagentPharma.com for more information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
Forward-Looking Statement
Statements contained in this press release contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give Sagent's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business as of the date of this release. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "will," "should," "can have," "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Sagent's expectations are not predictions of future performance, and future results may substantially differ from current expectations based upon a variety of factors, risks and uncertainties affecting Sagent's business, including, among others, the impact of competitive products and pricing and actions by Sagent's competitors with respect thereto; the timing of product launches; compliance with FDA and other governmental regulations by Sagent and its third party manufacturers; changes in laws and regulations; and such other risks detailed in Sagent's periodic public filings with the Securities and Exchange Commission, including but not limited to Sagent's most recent quarterly report on Form 10-Q and Sagent's IPO prospectus filed on April 21, 2011. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.